Keywords: Anti-PD-1/PD-L1; Immunotherapy; Immune checkpoint inhibitors; mRCC; Targeted therapies;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: AARI; Arctic and Antarctic Research Institute; CHNL; Centre for High North Logistics; OM; Operational Model; FSUE; Federal State Unitary Enterprise; H&M; Hull & Machinery; IAL; Institute of Arctic Logistics; IB; Icebreaker; IMO; International Maritime Org
Keywords: Systemic; Treatment; Older; mRCC;
Keywords: mRCC; Hospital volume; Systemic therapy; Kidney cancer; Volume-outcome association;
Keywords: Mammalian target of rapamycin; mRCC; Overall survival; Targeted therapy; Vascular endothelial growth factor;
Keywords: Biomarker; C-reactive protein; Neutrophil/lymphocyte ratio; Platelet/lymphocyte ratio; mRCC;
Keywords: mRCC; PPI; Targeted therapy; TKI; VEGF;
Keywords: CN; Kinetics; mRCC; Overall survival; Skeletal muscle index;
Keywords: neoplasm metastasis; carcinoma; renal cell; metastasectomy; CM; complete surgical metastasectomy; GRADE; Grading of Recommendations, Assessment, Development and Evaluation; mRCC; metastatic renal cell carcinoma; no-CM; incomplete or no surgical metastasec
Keywords: kidney; carcinoma; renal cell; neoplasm metastasis; interleukin-2; molecular targeted therapy; CR; complete response; ECOG; Eastern Cooperative Oncology Group; HDIL-2; high dose IL-2; IL-2; interleukin-2; mRCC; metastatic RCC; OS; overall survival; PD; pr
Keywords: First-line treatment; Kidney cancer; mRCC; Phase II; VEGFR inhibitor;
Keywords: mRCC; Targeted therapy; Sequential therapy; Overall survival; Prognostic markers; Predictive markers
Keywords: AM; adrenomedullin; AMF; autocrine motility factor; AML; acute myeloid leukemia; BCL; B-cell lymphoma; BCR; breakpoint cluster region; BM; bone marrow; CCL; chemokine (CâC motif) ligand; CML; chronic myeloid leukemia; ECM; extracellular matrix; EGF; epi
Keywords: kidney; carcinoma; renal cell; neoplasm metastasis; nomograms; prognosis; CCF; Cleveland Clinic Foundation; C-index; concordance index; ECOG; Eastern Cooperative Oncology Group; IMDC; International Metastatic Renal Cell Carcinoma Database Consortium; IRTL
Keywords: mRCC; sorafenib; sunitinib; thyroid function; TKI;
Keywords: Age; Geriatric; mRCC; Prognostic factors; Vascular endothelial growth factor
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
Keywords: mRCC; Intermediate risk; Overall survival; Poor risk; Sunitinib;
Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma
Keywords: kidney neoplasms; carcinoma; renal cell; neoplasm metastasis; nephrectomy; mortality; CN; cytoreductive nephrectomy; IPTW; inverse probability of treatment weighting; mRCC; metastatic RCC; NCDB; National Cancer Database; OS; overall survival; RCC; renal c
Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry
Keywords: Five-year OS; mRCC; RENSUR5 database; Russia; Treatment patterns;
Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma
Keywords: HIFs; hypoxia-inducing factors; RCC; renal cell carcinoma; VHL; von Hippel-Lindau; CTLs; cytotoxic T lymphocytes; mRCC; metastatic renal cell carcinoma; IL; interleukin; IFN; interferon; PD-1; programmed cell death-1; PD-L1; PD-ligand-1; CTLA-4; cytotoxic
Neuroprotective effect of 5É-androst-3β,5,6β-triol on retinal ganglion cells in a rat chronic ocular hypertension model
Keywords: COH; chronic ocular hypertension; CTB; cholera toxin subunit B; IOP; intraocular pressure; MDA; malonaldehyde; Mn-SOD; manganese superoxide dismutase; MRCC; mitochondrial respiratory chain complex; RGCs; retinal ganglion cells; ROS; reactive oxygen specie
Temsirolimus induced structural transition of cancerous renal cystatin to normal form in rats: In vitro mechanistic approach underlying renal cancer prevention
Keywords: FTIR; Fourier transformed infrared spectroscopy; RKC; rat kidney cystatin; CRKC; cancerous rat kidney cystatin; CD; circular dichroism; DMN; dimethylnitrosamine; RCC; renal cell carcinoma; mRCC; metastatic renal cell carcinoma; mTOR; mechanistic target of
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Keywords: mRCC; Dose reduction; Toxicity; Survival; Sunitinib; Pazopanib; First-line; Second-line;
Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience
Keywords: Adverse events; Alternate schedule; Efficacy; mRCC; Tyrosine kinase inhibitor;
Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib
Keywords: Angiogenesis inhibitor; c-Met inhibitor; mRCC; Prognostic marker;
Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus
Keywords: carcinoma; renal cell; neoplasm metastasis; thrombosis; vena cava; inferior; mortality; CN; cytoreductive nephrectomy; IMDC; International Metastatic Renal-Cell Carcinoma Database Consortium; IVC; inferior vena cava; MDACC; M. D. Anderson Cancer Center; m
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents
Keywords: Sorafenib; Sunitinib; Axitinib; Tivozanib; MRCC; Second line; First line; Phase III trial; Phase II trial;
Optimizing clinical benefit with targeted treatment in mRCC: “Tumor growth rate” as an alternative clinical endpoint
Keywords: Everolimus; mRCC; Tumor response; RECIST; Targeted therapies
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues
Keywords: Apoptosis; Drug safety; Imatinib; Narrow Therapeutic Index Drug (NTID); Receptor tyrosine kinase (RTK); Sunitinib; Toxicity; Tyrosine kinase inhibitor (TKI); Cell viability; ALL; acute lymphoblastic leukemia; AUC; area under the curve; b.i.d.; twice daily
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
Keywords: carcinoma; renal cell; neoplasm metastasis; survival; disease-free survival; biomarkers; ccRCC; clear cell renal cell carcinoma; IHC; immunohistochemistry; IRS; immunoreactivity score; mRCC; metastatic renal cell carcinoma; OS; overall survival; PFS; prog
Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data
Keywords: mRCC; mTOR inhibitors; Second-line; Sequence of therapy;
The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data
Keywords: PK; pharmacokinetic; DCE-MRI; dynamic contrast-enhanced magnetic resonance imaging; eTM; extended Tofts model; AIF; arterial input function; AIC; Akaike information criterion; mRCC; metastatic renal cell carcinoma; MFA; multiple flip angles; ROI; region o
Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database
Keywords: kidney; carcinoma; renal cell; nephrectomy; neoplasm metastasis; physician's practice patterns; CN; cytoreductive nephrectomy; mRCC; metastatic RCC; NCDB; National Cancer Data Base; RCC; renal cell carcinoma;
Kinetic models for the SR1500 and LY556 epoxies under manufacturer's recommended cure cycles
Keywords: Kinetic model; DSC; MRCC; Diffusion; Thermosetting resin;
Evidence and experience for the management of metastatic renal cell carcinoma
Keywords: Metastatic renal cell carcinoma; mRCC; Sunitinib; Axitinib; Temsirolimus; Guidelines; Sequencing
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications
Keywords: mTOR inhibitors; Oral Intravenous; Metastatic renal cell carcinoma; mRCC; Pharmacokinetics
Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials
Keywords: kidney; carcinoma, renal cell; neoplasm metastasis; risk; SEER program; ECOG; Eastern Cooperative Oncology Group; IFN; interferon-α; LDH; lactate dehydrogenase; mRCC; metastatic renal cell carcinoma; MSKCC; Memorial Sloan-Kettering Cancer Center; OS; ove
Percutaneous Cryoablation of Metastatic Renal Cell Carcinoma for Local Tumor Control: Feasibility, Outcomes, and Estimated Cost-effectiveness for Palliation
Keywords: ACER; adjunctive cost-effectiveness ratio; BSC; best supportive care; IFN; interferon; LYG; life-year gained; MCA; multisite cryoablation; mRCC; metastatic renal cell carcinoma; OS; overall survival; RCC; renal cell carcinoma; RF; radiofrequency;
Mechanism of Synergistic Antitumor Effect of Sorafenib and Interferon-α on Treatment of Renal Cell Carcinoma
Keywords: kidney; carcinoma; renal cell; sorafenib; interferon-alpha; antineoplastic combined chemotherapy protocols; CI; combination index; CTL; cytotoxic T lymphocyte; DC; dendritic cell; Fa; fraction affected; HLBI; human lymphoblastoid IFN-α; IC; inhibitory co
Large scale expansion of γ9δ2 T lymphocytes: Innacell γδ™ cell therapy product
Keywords: BrHPP; bromohydrin pyrophosphate; CTP; cell therapy product; DC; dendritic cells; FCS; foetal calf serum; 4%; HA; 4%; human serum albumin; mRCC; metastatic renal cell carcinoma; MNC; mononuclear cell; MM; multiple myeloma; NHL; non-Hodgkin's lymphoma; TNF
A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma
Keywords: kidney; kidney neoplasms; immunotherapy; cytokines; neoplasm metastasis; 5FU; 5-fluorouracil; ADCC; antibody dependent cellular cytotoxicity; BAY; BAY-43-9006; CA-IX; carbonic anhydrase IX; CR; complete response; CT; computerized tomography; HACA; human a